Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. NAVN
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
Amgen Inc (NASDAQ: AMGN) Delayed: 344.72 --0 (-0%)
Previous Close $344.72    52 Week High $176.85 
Open $344.72    52 Week Low $133.64 
Day High $344.72    P/E 51.92 
Day Low $344.72    EPS $6.64 
Volume 5,063